Tsukiyama I, Yamashita K, Kajiura Y, Ogino T, Akine Y, Egawa S, Yanagawa S
Department of Radiation Therapy, National Cancer Center Hospital, Tokyo, Japan.
Int J Hyperthermia. 1987 Nov-Dec;3(6):503-12. doi: 10.3109/02656738709140423.
Fifty-four patients with 65 superficial malignant lesions were treated by local hyperthermia combined with radiation therapy at the National Cancer Center Hospital, Tokyo. Hyperthermia was delivered with an Aloka Model HMS-020 (2450 MHz) or with a horn-type applicator of BSD-1000 (80-90 MHz). Relatively small tumours, those less than 4 cm in thickness, were treated by using 2450 MHz while 80-90 MHz delivered through the horn-type applicator was used for tumours exceeding 5 cm in thickness. The radiation dose was 4 Gy twice a week or 2 Gy five times a week, the total dose being 40-60 Gy. A total of six to 10 hyperthermia treatments ranging from 40 to 60 min each, with the tumour heated to more than 42.5 degrees C, were given twice a week within 1 h following radiation therapy. Complete response was achieved in 16 of the 30 patients (55 per cent) treated with the 2450 MHz microwave, and partial response in seven others (23 per cent). Tumours treated with the BSD-1000 achieved complete response in 10 out of 33 patients (30 per cent) and partial response in nine others (27 per cent). In five out of nine patients classified as partial responders, however, complete disappearance of tumour cells was noted by post-treatment histological examination. Complete plus partial response rates were thus essentially the same with the Aloka HMS-020 and the BSD-1000, though the rate of complete response was apparently higher with the Aloka unit, probably because it was used on smaller tumours.
东京国立癌症中心医院对54例患有65处浅表恶性病变的患者采用局部热疗联合放射治疗。热疗采用阿洛卡HMS - 020型(2450兆赫)或BSD - 1000型喇叭形辐射器(80 - 90兆赫)。相对较小的肿瘤,即厚度小于4厘米的肿瘤,采用2450兆赫进行治疗,而通过喇叭形辐射器输送的80 - 90兆赫则用于厚度超过5厘米的肿瘤。放射剂量为每周两次,每次4戈瑞,或每周五次,每次2戈瑞,总剂量为40 - 60戈瑞。在放射治疗后的1小时内,每周进行两次总共6至10次热疗,每次持续40至60分钟,将肿瘤加热至42.5摄氏度以上。使用2450兆赫微波治疗的30例患者中有16例(55%)达到完全缓解,另外7例(23%)达到部分缓解。使用BSD - 1000治疗的肿瘤,33例患者中有10例(30%)达到完全缓解,另外9例(27%)达到部分缓解。然而,在9例被归类为部分缓解的患者中,有5例在治疗后的组织学检查中发现肿瘤细胞完全消失。因此,阿洛卡HMS - 020和BSD - 1000的完全缓解加部分缓解率基本相同,尽管阿洛卡设备的完全缓解率明显较高,可能是因为它用于较小的肿瘤。